SequelSEC

Revium Rx. RVRC

Pharmaceutical Preparations · CIK 0001839140 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$14.30MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.23Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity2.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio3.87x51th

Revium Rx. (RVRC) reported net income of -$13.45M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Revium Rx.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Revium Rx. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
RevenueUnavailable
Cost of revenueUnavailable
Gross profitUnavailable
Operating incomeUnavailable
Net income-$13.45M
Research & developmentUnavailable
Weighted-average diluted sharesshares 60.73M
Pretax incomeUnavailable
Income tax expense$358.00K
Diluted EPS$-0.22
Selling, general & administrativeUnavailable
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Revium Rx. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$1.68M
Total assets$8.30M
Current assets$3.10M
Total liabilities$1.42M
Current liabilities$799.00K
Total equity incl. NCI$6.88M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$2.58M
Long-term debtUnavailable
Accounts payable$163.00K

Cash flow

Revium Rx. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flowUnavailable
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flowUnavailable
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Revium Rx. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio3.87x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RVRC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-31View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.